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ABSTRACT: In recent years, atmospheric cold plasma (ACP) has been widely investigated for 
potential application as an alternative decontamination technology in biomedical and healthcare 
sectors. In this study, the antimicrobial efficacy of ACP against Pseudomonas aeruginosa biofilms 
was investigated.  The 48-h biofilms were treated inside sealed polypropylene containers with a 
high-voltage dielectric barrier discharge (DBD) ACP (80 kVRMS) and subsequently stored for 24 
h at room temperature. Treatment for 60 s by either the direct or indirect mode of ACP exposure 
(inside or outside plasma discharge, respectively) reduced bacterial populations by an average of 
5.4 log cycles from an initial 6.6 log10 CFU/mL.  Increasing the treatment time from 60 s to 120 s 
and 300 s reduced biofilms to undetectable levels.  According to XTT assay (a metabolic activity 
assay), an extended treatment time of 300 s was necessary to reduce metabolic activity of cells in 
biofilms by an average of 70%. Further investigation of biofilm viability by confocal laser scan-
ning microscopy (CLSM) and scanning electron microscopy (SEM) demonstrated that extended 
ACP treatment had a detrimental effect on the viability of P. aeruginosa through disintegration of 
both bacterial cells and the biofilm matrix. The results of this study demonstrate the potential of 
a novel, in-package, high-voltage ACP decontamination approach for the inactivation of bacterial 
biofilms. 
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I. INTRODUCTION
Pseudomonas aeruginosa is one of the most abundant microorganisms in the natural 
environment and is a common opportunistic nosocomial pathogen, which causes a wide 
variety of acute and persistent infections in immunocompromised patients. This mi-
croorganism has become increasingly important due to associated prevalence, patho-
genicity, and increasing resistance to antimicrobial treatments, causing morbidity and 
mortality.1–2 Pseudomonas associated health care infections include respiratory tract 
infections,3–4 urinary tract infections,5 surgical and burn wound infections6,7 and blood-
stream infections.8,9 According to Neonatal Infection Surveillance Network, between 
2005 and 2011, in the United Kingdom, Pseudomonas spp. were responsible for 93% of 
neonatal infection outbreaks and with 18% of associated deaths.10 
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Water is the main environmental reservoir of P. aeruginosa, and the water distri-
bution system is one of the possible sources of P. aeruginosa in healthcare settings 
(taps, sinks, etc.).2,11 In addition, P. aeruginosa has a tendency to form biofilms. Re-
cently, Walker et al.12 demonstrated that, within hospital facilities in Northern Ireland, 
P. aeruginosa exists predominantly in the form of biofilm in water tap outlets, which 
are therefore a possible cause of infection. Biofilms are broadly described as a micro-
bially derived sessile community with altered phenotype with respect to growth rate, 
in which cells are attached to a substratum or to each other and are embedded in a ma-
trix of extracellular polymeric substances (EPSs).13 Material secreted by bacteria EPS 
(i.e., polysaccharides, proteins, lipids, and nucleic acids) act as a complex defensive 
mechanism protecting bacteria from unfavourable environmental conditions.  Due to 
the heterogeneous nature and multiple mechanisms of resistance, biofilms have an 
enormous impact on medicine.14 It has been estimated that up to 80% of human bacte-
rial infections are associated with biofilms.15 Once biofilms are established, different 
mechanisms account for resistance to antimicrobial treatments. In addition, inappro-
priate use or overuse of antibiotics may also result in increased bacterial resistance.16,17 
Therefore, alternative antimicrobial measures are required as a key component of the 
prevention of healthcare-associated infections (HAIs) to ensure effective reductions 
and elimination of pathogens and their associated biofilms while simultaneously 
averting bacterial resistance.
Atmospheric cold plasma (ACP) technology is an innovative field that is intensively 
researched for a range of different medical applications. Von Woedtke et al.18 classi-
fied plasma for medical application according to two general principles: indirect use of 
plasma to treat surfaces, materials, or devices for medical applications, and application 
of physical plasma on or within the human body. Sterilization of medical materials or 
devices (e.g., medical implants, catheters, or materials in blood purification systems) is 
the main use of indirect plasmas for medical purposes;20 whereas physical plasmas are 
under intense study for applications in wound healing,19,20 blood coagulation and skin 
regeneration,21 dentistry,22 and apoptosis of cancer cells.23 
To date, research on ACP sterilization has demonstrated effective reduction of clini-
cally important microorganisms in their planktonic state or in biofilms.24,25 However, the 
antimicrobial effects of plasma were reduced against biofilms by comparison with their 
planktonic counterparts.26–27
The aim of this study was to evaluate the potential of novel, in-package, high-volt-
age air DBD ACP for elimination of P. aeruginosa biofilm. The effects of treatment time 
and mode of plasma exposure were investigated. Surviving bacterial populations in bio-
film were estimated by colony count and XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophe-
nyl) [phenyl-amino)car-bonyl]-2H-tetrazolium hydroxide) assays for determination of 
cell viability and metabolic activity, respectively. The ability of the contained ACP reac-
tive species to penetrate complex biofilm structures was observed using a LIVE/DEAD 
bacterial viability kit followed by confocal scanning laser microscopy (CSLM). Scan-
ning electron microscopy (SEM) was conducted to observe morphological changes of 
biofilms caused by ACP treatment.
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II. MATERIALS AND METHODS
A. Bacterial Strains and Inocula Preparation
Pseudomonas aeruginosa ATCC 27853, a blood culture isolate, was obtained from the 
microbiology stock culture of the School of Food Science and Environmental Health of 
the Dublin Institute of Technology and was utilized in all experiments. A single isolated 
colony of the culture was inoculated in tryptic soy broth without glucose [TSB (-G), 
ScharlauChemie, Spain] and was incubated at 37°C for 18 h. The overnight culture was 
diluted in TSB to a density of 7.0 log10 colony-forming units per milliliter (CFU/mL), 
using the McFarland standard.  This bacterial cell concentration was further used as an 
inoculum for biofilm formation.
B. Biofilm Formation
Bacterial biofilms were produced in either 96-well plates for the colony count and XTT 
assay, on glass coverslips (24 x 32 mm) for CLSM analysis, or using tissue culture-treat-
ed inserts containing polycarbonate membrane (0.45 µm, Millicell, Millipore, Ireland) 
for SEM analysis.  Biofilms in the 96-well plates were obtained by adding 200 µl of TSB 
bacterial suspension (7.0 log10 CFU/ml) to the wells of the plates. For production of bio-
films for CLSM, coverslips were positioned inside the wells of the 6-well culture plate, 
and 8 ml of TSB bacterial suspension was added. For production of biofilms on polycar-
bonate membranes, inserts were placed inside the wells of the 6-well plate, which were 
filled with 2 ml of TSB bacterial suspension. The plates were incubated at 37°C for 48 
h. After 24 h of incubation, the supernatant from each well of the 96-well and 6-well 
plates containing inserts or glass coverslips was replaced with fresh TSB, with further 
incubation for 24 h. After incubation, the TSB containing suspended bacterial cells was 
removed and the wells were extensively rinsed with sterile PBS, leaving only bacterial 
biofilms for further investigation. Negative controls were obtained using TSB without 
inocula. Prior to each experiment, the biofilms were air dried for 60 min.
C. Experimental Design
The ACP system utilized a high-voltage DBD system previously described in Ziuzina et 
al.28 with a maximum voltage output of 120 kV at 50 Hz. The distance between the two 
15-cm diameter aluminium disk electrodes was 22 mm, which was equal to the height of 
the polypropylene container (310 x 230 x 22 mm) utilized as both a sample holder and 
as a dielectric barrier. For this study, ACP was generated in air at 80 kVRMS. 
The 96-well plates, glass coverslips or membrane inserts containing biofilms were 
placed in the center of the plastic container directly between the electrodes within the 
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plasma discharge for direct plasma treatment (Fig. 1A). For indirect plasma treatment, 
a separate container was used, and either substrate containing biofilm was placed to 
achieve treatment outside the plasma discharge (Fig. 1B). After sample loading, each 
container was sealed with a high-barrier polypropylene bag (Cryovac, B2630, USA) and 
placed between the aluminium electrodes of the transformer. The biofilms were treated 
with direct/indirect ACP for 0, 60 s, 120 s, and 300 s and were subjected to a post-treat-
ment storage for 24 h at room temperature. Control samples were untreated. All exper-
iments involving biofilm formation in 96-well plates were conducted using three inde-
pendently grown cultures and were repeated at least twice.  Experiments were repeated 
three times when biofilms were grown on glass coverslips and membrane inserts. 
FIG. 1: Schematic diagram of samples distributed within polypropylene container with respect 
to the electrodes: (a) direct treatment and (b) indirect treatment
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D. Biofilm Assays
1. Crystal violet assay (CV)
Crystal violet (CV) staining was used to monitor biofilm formation capacity using 24 
h and 48 h incubation times. Biofilm mass was quantified as described previously.29 
The absorbance was measured at 590 nm on a microplate reader (Synergy HT, Biotek 
Instruments, Inc.). Each absorbance value was corrected by subtracting the means of 
absorbance of a blank (uninoculated) TSB. Experiments were carried out in triplicate 
and were repeated at least twice.
2. Colony count assay
Following ACP treatment and 24 h post treatment storage, 200 µl of sterile PBS was 
added into the biofilm containing wells of the 96-well plate. To disrupt biofilms, the 
plates were sonicated using a water table sonicator (Bransonic 5510E-MT, Branson, 
USA) for 5 min. Suspensions were pooled together from the wells into sterile Eppendorf 
tubes, serially diluted in maximum recovery diluent (MRD, ScharlauChemie, Spain), if 
necessary, and 0.1-mL aliquots of appropriate dilutions were surface plated on TSA and 




Prior to each assay, fresh solution of 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl) [phe-
nyl-amino)car-bonyl]-2H-tetrazolium hydroxide (XTT, 1 mg/ml, Sigma-Aldrich, Ire-
land) was prepared as described previously.32 The wells containing biofilms and negative 
controls (TSB without inocula) were filled with sterile PBS (100 µl), then XTT-mena-
dione (100 µl) was added to all wells. Plates were incubated for 5 h at 37°C in the dark. 
After incubation, the supernatant (100 µl) from each well was transferred into the wells 
of a new 96-well microtiter plate, and the absorbance was measured at 486 nm on a mi-
croplate reader. The percentage of the surviving bacterial population was calculated as 
((AACP - AC) / A0) × 100%, where AACP, AC, and A0 are the absorbance of ACP treated, the 
negative control, and untreated control biofilms, respectively.
4. Confocal laser scanning microscopy (CLSM)
Prior to analysis, to differentiate viable and dead bacteria, untreated controls and biofilms 
treated with either direct or indirect ACP for 300 s were stained using a LIVE/DEAD 
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bacterial viability kit containing SYTO9 and propidium iodide (PI) (Sigma-Aldrich, 
Ireland). Biofilms grown on glass coverslips were covered with 200 µL of SYTO9, 
and the PI solution was prepared according to the manufacturer’s instructions and was 
incubated for 15 min in the dark. The samples were rinsed with sterile deionized water, 
placed on the microscope glass slide, and imaged using a Zeiss confocal microscope 
(Carl Zeiss, Model: LSM 510, Germany). The quantitative parameters to characterize 
biofilm thickness were obtained from CLSM stack images and the sample images were 
further analyzed by IMARIS image analysis software (Bitplane, Inc.). The maximum 
thickness of the biofilm was determined from the value of the Y-axis. 
5. Scanning electron microscopy (SEM)
For SEM analysis, untreated controls and P. aeruginosa biofilms treated directly or in-
directly with ACP for 300 s were selected and prepared as described by Gratao et al.,30 
with minor modifications. The cells were fixed in ice-cold 2.5% glutaraldehyde in 0.05 
M sodium cacodylate buffer (pH 7.4) (SCB) for 2 h. The cells were washed with the 
same buffer three times and were then fixed in 1% osmium tetroxide for 2 h at 4°C.  Af-
ter 2 h of fixation, bacterial cells were washed with SCB followed by three washes with 
distilled water. The samples were treated using increasing concentrations of ethanol 
(30%, 50%, 70%, 80%, 95%, and 99.5%) and dehydrated as described by Srey et al.31 
using 33%, 50%, 66%, and 100% (v/v) hexamethyldisilazane (Sigma-Aldrich, Ireland). 
To prevent surface charging by the electron beam, the samples were sputter-coated with 
gold particles using Emitech K575X Sputter Coating Unit resulting in a coating of 10 
nm after 30 s. The samples were examined visually using a FEI Quanta 3D FEG Dual 
Beam SEM (FEI Ltd, Hillsboro, USA) at 5 kV.
E. Statistical Analysis
Statistical analyses were performed using SPSS 19.0 (SPSS, Inc., Chicago, USA). The 
surviving populations of P. aeruginosa biofilms following ACP treatments were com-
pared using analysis of variance (ANOVA). Means were compared according to the 
method of Fisher’s least significant difference (LSD) at the 0.05 level.
III. RESULTS
A. Evaluation of Biofilm Biomass by CV Assay
According to the scheme described by Stepanovic et al.,32 24-h- and 48-h-old P. aerugi-
nosa demonstrated strong ability to produce biofilms (Fig. 2A).  Notably, after 48 h of 
incubation, P. aeruginosa biofilms were clearly visible on the surface of the wells of the 
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96-well microtiter plate (Fig. 2B). Based on these results, only bacterial biofilms grown 
for 48 h were used in further studies aimed at investigating the efficacy of ACP to inac-
tivate bacteria in not only the realistic but also the more resistant biofilm form.
B. Effects of ACP on P. aeruginosa biofilms Assessed by Colony Count 
and XTT Assays
The influence of ACP treatment time and mode of exposure on viability of P. aeruginosa 
biofilms based on colony count assay is presented in Fig. 3A. Generally, both direct and 
indirect modes of plasma exposure effectively reduced bacterial populations in biofilms 
after short treatment times. Prior to ACP treatment, an average population of bacterial 
biofilm attached on the surface of the wells was 6.6 log10 CFU/mL. ACP treatment for 60 
s reduced bacterial cells by an average of 5.4 log10 CFU/mL; increasing treatment time to 
120 s and 300 s reduced the numbers of viable cells within the biofilms to levels below 
detection limits (1.0 log10 CFU/mL). 
FIG. 2: (a) P. aeruginosa biofilm formation evaluated by CV assay after 24 h and 48 h of incu-
bation at 37°C; (b) P. aeruginosa biofilm formed in the wells of a 96-well microtiter plate. Top 
row:  uninoculated control wells. Bottom row: 48-h biofilm (yellow arrows)
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FIG. 3: (a) Surviving populations of P. aeruginosa 48-h biofilms assessed by colony count as-
say: untreated control biofilms (∆) after direct (◊) and indirect (□) ACP treatment. Vertical bars 
represent standard deviation. Limit of detection, 1.0 log10 CFU/sample (b) Percentage surviving 
populations of P. aeruginosa 48-h biofilms assessed by XTT assay: untreated control biofilms 
(∆), after direct (◊) and indirect (□) ACP treatment. Vertical bars represent standard deviation
Percentage survival of P. aeruginosa biofilm after ACP exposure based on XTT 
assay is presented in Fig. 3B. XTT absorbance values demonstrated that 60 s of direct 
and indirect treatment reduced metabolic activity of cells by 37% and 49%, respectively. 
Increasing treatment time from 60 s to 120 s further reduced cell metabolic activity by 
63% and 70% when exposed to direct and indirect treatment, respectively. However, no 
further reductions were observed by applying extended treatment time of 300 s, with a 
maximum average reduction of 70% recorded. Notably, post treatment storage time of 
24 h had a minor effect on biofilm activity for this microorganism based on both colony 
count and XTT assays. 
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C. Confocal Laser Scanning Microscopy (CLSM)
To evaluate the effect of ACP on viability of bacterial cells embedded in biofilm struc-
tures, CLSM analysis of untreated control and P. aeruginosa biofilms treated directly/
indirectly for 300 s was conducted. This analysis utilizes the mixture of SYTO9 (green 
fluorescent) and PI (red fluorescent) nucleic acid dyes.  SYTO9 labels bacterial cells 
with both intact and damaged membrane, whereas PI penetrates only cells with dam-
aged membrane. Therefore, this analysis allows determination of bacterial viability and 
cell membrane integrity on the basis of different colors, where green and red represent 
live and dead cells, respectively. The results of the CLSM analysis are presented in 
Fig. 4. As can be seen from Fig. 4A, the untreated control sample exhibited completely 
green fluorescence, i.e., only live cells were present. Maximum biofilm thickness of 
23 µm was recorded. Confocal images of biofilms treated with either direct or indirect 
ACP (Fig. 4B, 4C, respectively) displayed only red fluorescence, with no viable cells 
remaining after treatment. Moreover, images of ACP-treated samples also indicated a 
substantial reduction of biofilm thickness when compared with control biofilms. The 
thickness of biofilms was reduced to 8 µm and 6 µm after direct and indirect ACP treat-
ment, respectively. 
D. Scanning Electron Microscopy (SEM)
To examine the effects of ACP on P. aeruginosa biofilm distribution and morphology, 
SEM analysis of untreated control and samples treated directly or indirectly for 300 s 
was conducted. Figure 5A represents untreated controls, in which clustered rod-shaped 
bacterial cells are interconnected with each other by the complex biofilm matrix com-
ponents. Significant damage of bacterial cells and EPS was observed after both direct 
FIG. 4: CLSM images of P. aeruginosa 48-h biofilm stained with LIVE/DEAD bacterial vi-
ability kit: (a) untreated control; (b) 300 s of direct ACP treatment; (c) 300 s of indirect ACP 
treatment. Cells stained green are alive and cells stained red are dead
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and indirect ACP treatments. Complete disintegration of cells and biofilm matrix was 
noted after direct ACP treatment: biofilms were converted into the ‘sponge-like,’ irregu-
larly shaped debris compared with untreated controls (Fig. 5B). Although indirect ACP 
had similar destructive effects on biofilm structures, small fractions of EPS components 
were still detected after the treatment (Fig. 5C).
IV. DISCUSSION
In recent years, cold atmospheric plasma (ACP) has been widely investigated as an al-
ternative sterilization technology for potential application in medicine. This technology 
has been demonstrated to have great bactericidal effects against a wide range of micro-
organisms with high potential to avoid any thermal damage to both living and non-liv-
ing biomedical structures.33 Our previous studies demonstrated that high-voltage DBD 
ACP in conjunction with treatment of contaminated objects inside sealed packages and 
following post treatment storage was very effective for inactivation of bacteria in their 
planktonic form, reducing the numbers within seconds.31 However, bacterial biofilms, 
as a predominant mode of microbial growth,34 represent major challenges in industrial 
and health care settings due to their increased mechanical stability and antimicrobial 
resistance.35 Therefore, in the present study, the potential of ACP to inactivate bacterial 
pathogens was investigated against challenge P. aeruginosa biofilms, as one of the ma-
jor causes of healthcare-associated infections. 
P. aeruginosa is considered a model microorganism for biofilm research due to its 
excellent ability to form biofilm.36 Because bacteria in older biofilms are more resistant 
to antimicrobial treatments,37,38 only biofilms grown for 48 h were utilized to present 
a realistic challenge to the ACP treatment. The effect of ACP treatment on P. aerugi-
nosa biofilms was investigated utilizing widely accepted plate-count and XTT assays. 
According to the results obtained from both assays, no significant difference between 
the effects of direct and indirect modes of exposure on bacterial biofilms was found. 
According to colony counts, rapid inactivation of cells in biofilm was achieved after 
FIG. 5: SEM images of P. aeruginosa 48-h biofilm: (a) untreated control; (b) 300 s of direct ACP 
treatment; (c) 300 s of indirect ACP treatment
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relatively short treatments (60 s), resulting in reduction of bacterial levels by 5.4 log10 
CFU/ml. With lower inactivation rates, however, bacterial populations were below de-
tection limits after exposure to 120 s and 300 s of treatment. Similarly, Alkawareek et 
al.39 reported biphasic reductions of P. aeruginosa biofilms due to ACP treatment, where 
initial 60 s of plasma treatment resulted in rapid decline in bacterial levels, causing 
slower reduction between 60 s and 240 s of treatment. In general, our data suggest that 
80kV air in-package DBD ACP treatment exhibits considerably high inactivation po-
tential against the most abundant and resistant bacterial form—biofilm. Notably, based 
on our preliminary data, treatment for only 30 s was required to completely eliminate P. 
aeruginosa (~7.0 log10 CFU/ml reduction) in the planktonic form (data not shown). In 
general, according to previous reports, focusing on inactivation efficacy of ACP against 
biofilm, complete inactivation of P. aeruginosa biofilm could be achieved after longer 
treatment times, from 5 to 10 min.27,40 Utilization of different ACP systems and different 
approaches to biofilm formation are probably the main reasons for variations in the pub-
lished reports, which reduces the possibility of drawing adequate conclusions regarding 
the overall plasma treatment effectiveness against bacterial biofilms. Comprehensive 
system, process, and target comparative studies are still required. 
To examine the effects of ACP on the metabolic state of P. aeruginosa biofilms, the 
XTT assay was utilized, which involves intracellular reduction of XTT to a water-sol-
uble formazan, the absorbance of which is proportional to the number of metabolically 
active bacterial cells.32 This method has been successfully utilized to measure the re-
spiratory activity of bacteria after application of different sanitizers as well as ACP.27,41 
According to the results obtained from the XTT assay, even after extended treatment 
time of 300 s, an average of 30% of cells in biofilms were still metabolically active. This 
outcome was also observed by Alkawareek et al.,42 who reported that ACP inactivated 
85% of P. aeruginosa cells according to colony counts, while the XTT absorbance value 
corresponded to 36%. Borges et al.42 observed similar bacterial response to stress, when 
P. aeruginosa biofilm was subjected to naturally derived compounds with 30% of cell 
metabolic activity remaining after the treatment. In general, the plate count assay ac-
counts only for culturable bacterial cells and does not take into account cells that might 
still be metabolically active. Bacteria that fail to grow on the bacteriological media 
but are still alive are described as a viable but nonculturable (VBNC) state of bacteria. 
This result has been demonstrated for many microorganisms when facing environmental 
stress, including P. aeruginosa.43,44 Bacteria in a VBNC state can regain culturability and 
can retain virulence, even when they are in the nonculturable state. Therefore, VBNC 
bacteria  may contribute to further contamination.45 
CLSM, in conjunction with nucleic acid dyes SYTO9 and PI, was used to evalu-
ate the effects of ACP treatment on viability and cell membrane integrity. Microscopic 
observations demonstrated that the bacterial cell membrane was completely ruptured 
following treatment, which indicates the potential destruction abilities of the high-volt-
age system used. Although high sterilization potential is among the main characteristics 
and advantages of every antimicrobial technique, physical removal of bacterial biofilms 
is another important criteria that is gaining increased attention, specifically in plasma 
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biofilm research. Confocal microscopy analysis also demonstrated that ACP treatment 
was able not only to successfully inactivate cells through penetration inside complex 
bacterial aggregates but also to substantially remove the biofilm from the associated 
surface, which was identified by measuring the biofilm thickness. 
The results of this work also point to the complex interaction between reactive spe-
cies generated by air plasma and biofilms. As is commonly known, air plasma is an 
excellent source of electrons and positive and negative ions, free radicals, stable con-
version products (e.g., ozone), excited atoms and molecules, and ultraviolet radiation 
photons.46 The main mechanism of action of ACP reactive species is the diffusion of 
oxygen species through the bacteria cell wall, which causes local damage to the cyto-
plasmic membrane, protein and DNA strands, as well as physical effects by causing mi-
crobial etching and erosion.47,48 In this study, to monitor the physical changes caused by 
ACP treatment, SEM analysis of biofilms was conducted. The microscopic images en-
abled observation of the differences between control (untreated) samples, which proved 
biofilm complexity and the resulting challenge linked to antimicrobial resistance, and 
treated samples, where cells and biofilm components were significantly damaged by the 
action of ACP. 
Notably, the in-package, high-voltage ACP treatment used a 24-h post treatment 
storage time. This allowed the retention of plasma reactive species inside the pack over 
time, thus facilitating bactericidal action of these species on biofilm samples. This ap-
proach is more likely to show increased antimicrobial effects of plasma, the mechanism 
of which is mainly based on the reaction of long-lived and recombined species rather 
than on charged particles or short-lived species, which are more relevant to effects noted 
using treatment without post treatment storage. This approach could contribute to an 
increased potential of plasma species to penetrate complex biofilm matrices further in-
activating the cells. However, there are several limitations in this work.  It is known that 
formation of biofilms is influenced by environmental conditions and characteristics of 
substrates to which bacteria attach. In this study, the model system, a 96-well microtiter 
plate, was utilized for biofilm development, which cannot holistically describe the broad 
range of materials implicated in biofilm formation within clinical environments. More-
over, it is more likely that, in real clinical environments, biofilm communities may be 
inhabited by numerous different species and that interactions among these species could 
contribute to the organization of multispecies biofilms. Multispecies biofilms are usually 
more resistant against antimicrobial treatments than monospecies biofilms.49 Therefore, 
further studies on the efficacy of ACP against multispecies biofilms developed on a wid-
er range of relevant materials may be warranted.
IV. CONCLUSION 
The results of this study clearly demonstrate that in-package, high-voltage air DBD ACP 
in conjunction with post treatment storage is very effective against complex bacterial 
biofilms. With relatively short treatment of 60 s, it was possible to achieve substantial 
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reductions (5.4 log10 CFU/ml) of 48-h-old P. aeruginosa biofilms. In this study, a series 
of methods were utilized to monitor the changes in biofilms caused by ACP treatment, 
namely, colony count, XTT assay, CLSM, and SEM, elucidating information regarding 
different parameters associated with the viability of cells in biofilms. In terms of meta-
bolic activity, 30% of cells survived extended treatment for 300 s, whereas, according 
to colony count, there were no bacterial survivors. These results indicate a possible in-
duction of VBNC state of bacteria due to the stress caused by ACP treatment. However, 
CLSM and SEM analyses indicate that extended treatment caused severe damage to P. 
aeruginosa cell membranes and effectively disrupted heterogeneous biofilm structures. 
However, better understanding of interactions between plasma ACP reactive species 
and biofilm components and identification of specific biofilm targets will allow further 
optimization of ACP treatment parameters toward more effective and less damaging 
sterilization required in the field of medicine. 
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